Nanoliposomes Meet Folic Acid: A Precision Delivery System for Bleomycin in Cancer Treatment

Authors

  • Davoud Shakiba Zhejiang University, School of Medicine, Hangzhou, China.
  • Aida Mohammadiun Shabestari Zhejiang University, School of Medicine, Hangzhou, China.
  • Tahere Mokhtari Department of Pathology, University of Pittsburgh, PA, USA.
  • Mahyar Khanlari Goodarzi College of Dentistry, University of East, Manila, Philippines.
  • Saboor Saeed Zhejiang University, School of Medicine, Hangzhou, China.
  • Zeinab Zinatbakhsh Department of Animal Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
  • Kiomars Akaberi Departmant of Audiology, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mohammadreza Allahyartorkaman Department of Life Science, College of Life Science, National Taiwan University, Taipei, Taiwan.

Keywords:

Targeted drug delivery, Folate receptor (FR), Cytotoxicity, Bleomycin, Nanoliposomes

Abstract

Overview: The targeted administration of anticancer therapies, particularly through folate receptor (FR)-mediated targeting, enhances treatment effectiveness while minimizing side effects. This study assesses the therapeutic potential of folate-targeted liposomal bleomycin (FL-BLM) against traditional forms in treating human ovarian carcinoma and oral cancer.

Methods: FL-BLM was created using the thin film hydration technique with folic acid integration for active targeting. Its efficacy was compared to non-targeted liposomal bleomycin (L-BLM) and traditional bleomycin (BLM) using the MTT assay and flow cytometry to measure G2/M phase cell cycle arrest.

Results: FL-BLM demonstrated significantly greater effectiveness in reducing cell viability and inducing G2/M phase arrest in oral cancer cells (HN cells, OECM-1) and ovarian cancer cells (A2780CP) compared to L-BLM and BLM, indicating successful folate-mediated targeting.

Conclusions: FL-BLM effectively targets and inhibits FR-overexpressing cancer cells, particularly in both cancers. This supports the potential of folate-mediated targeting in liposomal drug delivery systems for improving drug delivery and reducing toxicity. Future research should further explore FR-targeted therapies across various cancer types

Downloads

Published

2024-11-26

Issue

Vol. 9 No. 4 (2024)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).